Eugenol / BAD Cancer Research Results

Eug, Eugenol: Click to Expand ⟱
Features:

Eugenol — Eugenol is a naturally occurring phenylpropanoid and volatile aromatic phenol most strongly associated with clove oil from Syzygium aromaticum. Eugenol is a phenolic aromatic ingredient that is chiefly derived from clove oil. It is formally classified as a small-molecule phytochemical, essential-oil constituent, food-flavouring agent, and experimental anticancer adjunct rather than an approved oncology drug. Standard abbreviations include EUG and 4-allyl-2-methoxyphenol. It is also present in cinnamon, basil, bay, nutmeg, and other aromatic plants. The oncology evidence is mainly preclinical, with strongest support for apoptosis induction, PI3K/Akt suppression, anti-metastatic effects, and chemo/radiosensitization in cell and animal models. clove oil has been advertised as a dental pain-relieving agent and germicide, and is used in mouthwashes and pharmaceutical drugs. Eugenol (4-allyl (-2-mthoxyphenol)), a phenolic natural compound available in honey and in the essential oils of different spices such as Syzgium aromaticum (clove), Pimenta racemosa (bay leaves), and Cinnamomum verum (cinnamon leaf).
-eugenol is the major ingredient of three spices (i.e. clove, cinnamon,and nutmeg)
-clear to pale yellow liquid with an oily consistency and a spicy aroma. It is sparingly soluble in water and well soluble in organic solvents.
-entering the systemic circulation within 30-60 minutes, paradoxically limits it therapeutic effectiveness.

Primary mechanisms (ranked):

  1. Induction of intrinsic and extrinsic apoptosis through mitochondrial dysfunction, Bax/Bcl-2 shift, cytochrome-c release, caspase activation, and PARP cleavage.
  2. Suppression of PI3K/Akt/mTOR and related survival signalling, including FOXO3a-linked autophagy/apoptosis in breast cancer models.
  3. Anti-inflammatory transcriptional modulation, especially ↓ NF-κB, ↓ COX-2, ↓ inflammatory cytokine signalling, and context-dependent STAT3/IL-6 axis suppression.
  4. Anti-metastatic and anti-invasive activity through ↓ MMP-2/MMP-9, ↓ migration, ↓ invasion, and reduced epithelial-mesenchymal transition markers in selected models.
  5. Anti-angiogenic effects through ↓ VEGF-linked signalling and reduced invasion/angiogenesis markers in gastric and other cancer models.
  6. ROS redox modulation with model-dependent pro-oxidant stress in cancer cells and antioxidant/anti-inflammatory effects in non-malignant contexts.
  7. Chemosensitization and radiosensitization, reported preclinically with cisplatin, gemcitabine, and ionizing radiation, but not clinically established.

Bioavailability / PK relevance: Eugenol is rapidly absorbed and extensively metabolized, mainly through conjugation pathways, so systemic exposure is transient and formulation-dependent. Its volatility, lipophilicity, rapid metabolism, and local irritation risk make delivery strategy important. Nanoemulsions, encapsulation, and conjugated delivery systems are being explored preclinically to improve stability, exposure, and tumour delivery.

In-vitro vs systemic exposure relevance: Many in-vitro anticancer studies use micromolar-to-high-micromolar concentrations that may exceed freely achievable systemic exposure after ordinary dietary or flavouring-level intake. Low-dose mechanistic reports exist in some breast cancer models, but translation remains uncertain. Essential-oil or clove-derived exposure should not be equated with purified eugenol pharmacology because source composition, dose, and route strongly affect exposure.

Clinical evidence status: Preclinical. Eugenol has cell-line and animal-model anticancer evidence, plus limited adjunctive clinical-context use in aromatherapy or topical/dental products, but there is no established clinical evidence supporting eugenol as a cancer treatment. Registry-visible oncology studies involving essential oils generally assess symptom support or mixtures, not purified eugenol as an anticancer therapeutic.

Eugenol Cancer Mechanism Table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondrial apoptosis and caspases ↑ Bax, ↑ cytochrome-c, ↑ caspase-3/8/9, ↓ Bcl-2, ↓ PARP integrity Mixed; cytoprotection at low exposure but irritation/cytotoxicity at high exposure R/G Apoptotic tumour-cell killing Core and most reproducible anticancer axis across breast, cervical, gastric, lung, and other models.
2 PI3K Akt mTOR survival signalling ↓ PI3K/Akt, ↓ mTOR signalling, ↑ FOXO3a activity, ↑ autophagy/apoptosis Context-dependent R/G Reduced survival signalling and increased treatment vulnerability Highly relevant in breast cancer and lung cancer models; may overlap with HER2/PI3K-Akt effects.
3 NF-κB COX-2 inflammatory signalling ↓ NF-κB, ↓ COX-2, ↓ inflammatory cytokine signalling ↓ inflammatory signalling in non-malignant inflammatory contexts R/G Anti-inflammatory and anti-survival transcriptional pressure Important bridge between anticancer and general anti-inflammatory pharmacology.
4 MMP invasion and metastasis ↓ MMP-2, ↓ MMP-9, ↓ migration, ↓ invasion Context-dependent G Anti-invasive and anti-metastatic activity Mechanistically meaningful for breast, fibrosarcoma, gastric, and lung cancer models.
5 Angiogenesis and VEGF-linked signalling ↓ VEGF-linked angiogenic markers, ↓ invasion-associated vascular support Context-dependent; excessive exposure may irritate tissues G Reduced tumour vascularization support Best supported in animal carcinogenesis and metastasis-associated models rather than clinical oncology.
6 Cell cycle arrest ↑ p21, ↑ p27, ↓ cyclin-linked proliferation, S-phase or G2/M effects depending on model Context-dependent G Reduced proliferation Secondary but common contributor to antiproliferative activity.
7 Mitochondrial ROS redox stress ↑ ROS or redox stress in some cancer models; antioxidant effects in others Often ↓ oxidative stress at low exposure; irritation or toxicity possible at high exposure P/R/G Context-dependent redox modulation Do not tag simply as antioxidant. Cancer-cell effect can be pro-oxidant, antioxidant, or mixed depending on dose, timing, and model.
8 NRF2 antioxidant response Mixed or context-dependent; not a primary anticancer-defining axis Potential ↑ cytoprotective antioxidant response in non-malignant stress models G Secondary redox adaptation Include only as secondary/contextual unless a specific study demonstrates NRF2-dependent cancer-cell modulation.
9 Glycolysis and metabolic reprogramming Metabolomic shifts reported; likely ↓ proliferative metabolic fitness in selected CRC/oral cancer contexts Unclear G Metabolic stress Mechanistically interesting but less mature than apoptosis, PI3K/Akt, and invasion axes.
10 Chemosensitization ↑ cisplatin cytotoxicity, ↑ gemcitabine activity, ↑ apoptosis Potential normal-cell toxicity not adequately defined R/G Adjunctive treatment sensitization Preclinical only; promising but insufficient for clinical-use claims.
11 Radiosensitization ↑ ionizing-radiation cytotoxicity in cervical and oral cancer models Normal-tissue protection versus sensitization remains unresolved R/G Radiation response enhancement Preclinical only; should be tagged as experimental radiosensitizer, not clinically validated.
12 Clinical Translation Constraint In-vitro exposure may exceed realistic free systemic levels High-dose clove oil/eugenol can irritate mucosa and has overdose hepatotoxicity risk G Limits direct translation Major constraints are rapid metabolism, dose-limited tolerability, formulation dependence, lack of oncology trials, and distinction between food-level GRAS use and therapeutic dosing.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr



BAD, BCL2 associated agonist of cell death: Click to Expand ⟱
Source:
Type:
BCL2 associated agonist of cell death (BAD) protein is a pro-apoptotic member of the Bcl-2 gene family.
Expression of the BAD is associated with the development and progression of cancer.


Scientific Papers found: Click to Expand⟱
6388- Eug,    Eugenol’s anti-cancer properties, its modulation of signalling pathways, and cascades across various cancers: A review
- Review, Var, NA
Dose↝, Eugenol, a significant bioactive compound, is found in cloves and other traditional Indian medicinal plants, such as cinnamon, tulsi, ginger, turmeric, and Japanese star anise, which have been reported to have significant anticancer properties.
AntiCan↑,
*Inflam↓, also exhibits different pharmacological effects (anti-inflammatory, cardio-protection, and neuroprotection).
*cardioP↑,
*neuroP↑,
angioG↓, eugenol exhibits anti-apoptotic, anti-angiogenic, and anti-metastatic properties in cancer cell lines and in vivo animal models, which we discuss in this review.
TumMeta↓,
*BioAv↑, Oral administration of eugenol promoted rapid absorption by different organs and metabolism in the liver. encapsulation is required to address the issues of early absorption, increased water solubility, and improved efficiency
*CompStab↑, Eugenol encapsulation as an inclusion with β-cyclodextrin, chitosan, and 2-hydroxypropyl-β-cyclodextrin nanoparticles improves its thermal stability
*toxicity↝, Eugenol at lower doses displayed minimal adverse effects, including contact dermatitis, local irritation, and rare allergic responses. However, at its higher doses, it can lead to liver and kidney damage, tissue injury, sudden onset of seizures, and
antiNeop↑, exhibit antineoplastic properties against different cancers by triggering cell cycle arrest and apoptosis in cancer cells
TumCCA↑,
Apoptosis↑,
*antiOx↑, Eugenol exhibits its antioxidant property due to its unique structural configuration, specifically the presence of an allyl group, as revealed by electron spin resonance
*lipid-P↓, Eugenol prevents lipid peroxidation (Nagababu and Lakshmaiah 1994), hexanal oxidation (Lee and Shibamoto 2001), copper-dependent LDL oxidation, and nonenzymatic peroxidation in liver mitochondria
*ROS↓, Eugenol exhibited 58–81 % DPPH radical scavenging potential in its 0.25–1.0 µM/ml concentration
*SOD↑, Eugenol protects against oxidative damage by increasing the levels of certain antioxidant enzymes, such as SOD, CAT, GST, and GPx (Huang et al. 2015).
*Catalase↑,
*GSTs↑,
*GPx↑,
*iNOS↓, Eugenol pre-treatment increased the levels of antioxidant enzymes and decreased the expression of iNOS, COX2, IL-6, and tumor necrosis factor-α (TNF-α) (Kaur et al. 2010).
*COX2/PTGS2↓,
*IL6↓,
*TNF-α↓,
*AntiArt↑, Administration of eugenol at 33 mg/kg dose in arthritis-induced male Sprague-Dawley rats decreased the swelling of paws and joints (
*Bacteria↓, Along with cinnamaldehyde and thymol, Li et al. determined eugenol's antibacterial activity against E. coli and S. aureus.
TumAuto↑, eugenol activated apoptosis and autophagy through the PI3K/AKT/FOXO3a pathway in cancer cells(breast cancer cells).
PI3K↓, PI3K/Akt/mTOR pathway inhibition
Akt↓,
FOXO3↝,
BAX↑,
mTOR↓, PI3K/Akt/mTOR pathway inhibition
NF-kB↓, NF-κB signaling pathway inhibition
P53↑, In some cancers, eugenol has been shown to upregulate p53, thereby inhibiting cancer growth.
TumCG↓,
CSCs↓, eugenol downregulated certain signaling cascades of the Wnt signaling pathway and specific cancer stem cell markers, including CD44, EpCAM, Notch1, and Oct4, in breast cancer cell lines treated with eugenol.
CD44↓,
EpCAM↓,
NOTCH1↓,
OCT4↓,
Bcl-2↓, Eugenol also downregulates the protein expressions of p85, BCL-2, PDK1, HER2, AKT, BAD, Cyclin D1, and NF-KB.
PDK1 / PDPK1↓,
HER2/EBBR2↓,
BAD↓,
cycD1/CCND1↓,
ROS↑, EUG-medium chain triglyceride nanoemulsions Liver cancer HB8065 cells Increased the levels of ROS generation to initiated the apoptotic cell death
Casp3↑, apoptosis initiated by Caspase-3 protein upregulation
selectivity↑, Eugenol was not cytotoxic to MCF10A cells; however, it displayed cytotoxic activity in the transformed MCF10A cells (MCF10A-ras).
MMP2↓, A significant decline in matrix metalloproteinase (MMP-2, MMP-9) levels and an increase in tissue inhibitor of metalloproteinase-1 (TIMP-1) expression were also observed.
MMP9↓,
TIMP1↑,
VEGF↓, Eugenol also inhibits metastatic invasion and angiogenesis, as evident from the downregulation of MMP-2, MMP-9, VEGF, and VEGFR1, along with the upregulation of RECK and TIMP-2
VEGFR1↓,
RECK↑,
TIMP2↑,
DNAdam↑, Eugenol demonstrated an apoptosis-inducing effect in HL-60 cells, as evidenced by DNA fragmentation and a DNA ladder assay.
MMP↓, It is accompanied by a decline in mitochondrial membrane potential and thiol levels, early disruption of the lipid layer, DNA fragmentation, and activation of proapoptotic markers (Caspase-3, PARP, p53)
Thiols↓,
PARP↑,
*Pain↓, eugenol nanoemulsion may significantly reduce pain-associated arteriovenous fistula (AVF)
E2Fs↓, t interferes with several critical cancer signaling pathways, including the Wnt/b-Catenin pathway, PI3K/AKT pathway, MAPK/ERK pathway, E2F1/survivin pathway, JNK/STAT3 pathway, and NF-κB signaling pathway, among others.
survivin↓, cause E2F1/survivin downregulation, which activates apoptosis in breast cancer cells

6389- Eug,    Molecular Insights into the Management of Eugenol's Anticancer Action Against Colon Cancer: A Detailed Review
- Review, Colon, NA
Apoptosis↓, Eugenol’s multitargeted action encompasses apoptosis induction, cell cycle arrest, suppression of inflammatory pathways, and inhibition of metastatic progression.
TumCCA↓,
Inflam↓,
TumMeta↓,
BioAv↑, nanotechnological encapsulation strategies have been explored to enhance bioavailability and pharmacokinetic stability.
eff↓, The compound is susceptible to oxidation when exposed to light, atmospheric oxygen, and elevated temperatures[2].
Half-Life↓, eugenol undergoes rapid absorption across the gastrointestinal epithelium, entering the systemic circulation within 30-60 minutes[3]. The swift absorption profile, while ensuring bioavailability, paradoxically limits it therapeutic effectiveness
*ROS↓, eugenol inhibits the endogenous production of reactive oxygen species (ROS) and reactive nitrogen species (RNS)
*RNS↓,
*SOD↓, Eugenol augments the body’s intrinsic antioxidant defense mechanisms, elevating expression of cytoprotective enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione S-transferases (GSTs)
*Catalase↑,
*GSTs↑,
*MAOA↓, Through monoamine oxidase (MAO) inhibition, eugenol modulates neurotransmitter homeostasis in the central nervous system, offering neuroprotective benefit
*neuroP↑,
*DNAdam↓, By eliminating reactive molecular species and preventing accumulation of damaged DNA and proteins, eugenol reduces the likelihood of mutations
Apoptosis↑, Multiple investigations have demonstrated eugenol’s capacity to induce apoptosis in diverse colon cancer cell lines, including HT-29, HCT-116, Caco-2, and SW-620
ROS↑, In human promyelocytic leukemia cells (HL-60) and colorectal cancer models, eugenol triggers elevated intracellular ROS accumulation
selectivity↑, This pro-oxidant activity in cancer cells contrasts sharply with eugenol’s cytoprotective antioxidant effects in normal cells, illustrating its selective anticancer action
MMP↓, Loss of mitochondrial membrane integrity triggers cytochrome c release into the cytosol, activating the caspase-9/caspase-3 cascade and culminating in programmed cell death
Cyt‑c↓,
Casp3↑,
Casp9↑,
TumCD↑,
BAX↑, Eugenol enhances expression of the tumor suppressor protein p53, which transactivates pro-apoptotic genes (BAX, BAD, APAF-1) while suppressing anti-apoptotic genes (BCL-2, BCL-XL)
BAD↑,
APAF1↑,
Bcl-2↓,
Bcl-xL↓,
P53↑,
cl‑PARP↑, eugenol activates executioner caspases-3 and -7, facilitating cleavage of critical substrates (PARP, DFF45) and morphological manifestations of apoptosis
TumCCA↑, Eugenol-treated cancer cells exhibit accumulation at the G2/M phase transition, accompanied by downregulation of cell cycle-promoting proteins (cyclin D1, cyclin B1, CDK2, CDK4) and upregulation of CDK inhibitors (p21, p27)
cycD1/CCND1↓,
CycB/CCNB1↓,
CDK2↓,
CDK4↓,
P21↑,
p27/CDKN1B↑,
NF-kB↓, Eugenol inhibits IκB-α phosphorylation, preventing NF-κB nuclear translocation and transcriptional activity[
COX2/PTGS2↓, Eugenol downregulates COX-2 expression, reducing pro-tumorigenic prostaglandin production and associated inflammation[3]
PGE2↓,
MAPK↓, Suppression of MAPK cascade reduces cancer cell proliferation and survival
PI3K↓, PI3K/Akt/mTOR Pathway Blockade
Akt↓,
mTOR↓,
MMPs↓, Eugenol suppresses MMP expression and activity, reducing tumor cell invasive capacity
EMT↓, Eugenol suppresses EMT-promoting transcription factors (Snail, Slug, ZEB1), maintaining E-cadherin expression and cellular adhesion[5].
Snail↓,
Slug↓,
Zeb1↓,
E-cadherin↑,
ChemoSen↑, Emerging evidence suggests eugenol enhances anticancer efficacy of conventional chemotherapeutic agents[5][6].
CompStab↑, nanotechnological encapsulation strategies have been explored to enhance bioavailability and pharmacokinetic stability.

6337- Eug,    Eugenol alleviated breast precancerous lesions through HER2/PI3K-AKT pathway-induced cell apoptosis and S-phase arrest
- in-vitro, BC, MCF-10AT
TumCP↓, 80 μM eugenol could significantly inhibit the proliferation of HER-2 positive MCF-10AT cells and the inhibition rate was up to 32.8%,
TumCCA↑, Eugenol also significantly induced human breast precancerous lesion MCF-10AT cell apoptosis and cell cycle S-phase arrest
HER2/EBBR2↓, In MCF-10AT cells treated by 180 μM eugenol, the protein expressions of HER2, AKT, PDK1, p85, Bcl2, NF-κB, Bad and Cyclin D1 were decreased
Akt↓,
PDK1 / PDPK1↓,
Bcl-2↓,
NF-kB↓,
BAD↓,
cycD1/CCND1↓,


Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 2,   Thiols↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

PDK1 / PDPK1↓, 2,  

Cell Death(tgid=5) ⓘ

APAF1↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 2,   BAD↓, 2,   BAD↑, 1,   BAX↑, 2,   Bcl-2↓, 3,   Bcl-xL↓, 1,   Casp3↑, 2,   Casp9↑, 1,   Cyt‑c↓, 1,   survivin↓, 1,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 3,   HER2/EBBR2↓, 2,   MAPK↓, 1,   mTOR↓, 2,   PI3K↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

FOXO3↝, 1,   OCT4↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↑, 2,   PARP↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 3,   E2Fs↓, 1,   P21↑, 1,   p27/CDKN1B↑, 1,   TumCCA↓, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 1,   NOTCH1↓, 1,   TumCG↓, 1,   TumCP↓, 1,  

Migration(tgid=13) ⓘ

E-cadherin↑, 1,   EMT↓, 1,   EpCAM↓, 1,   MMP2↓, 1,   MMP9↓, 1,   MMPs↓, 1,   RECK↑, 1,   Slug↓, 1,   Snail↓, 1,   TIMP1↑, 1,   TIMP2↑, 1,   TumMeta↓, 2,   Zeb1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   VEGF↓, 1,   VEGFR1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD44↓, 1,   COX2/PTGS2↓, 1,   Inflam↓, 1,   NF-kB↓, 3,   PGE2↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   ChemoSen↑, 1,   CompStab↑, 1,   Dose↝, 1,   eff↓, 1,   Half-Life↓, 1,   selectivity↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

HER2/EBBR2↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   antiNeop↑, 1,  
Total Targets: 73

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 2,   GPx↑, 1,   GSTs↑, 2,   lipid-P↓, 1,   RNS↓, 1,   ROS↓, 2,   SOD↓, 1,   SOD↑, 1,  

Cell Death(tgid=5) ⓘ

iNOS↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IL6↓, 1,   Inflam↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

MAOA↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   CompStab↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiArt↑, 1,   cardioP↑, 1,   neuroP↑, 2,   Pain↓, 1,   toxicity↝, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 25

Scientific Paper Hit Count for: BAD, BCL2 associated agonist of cell death
3 Eugenol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:399  Target#:426  State#:%  Dir#:%
wNotes=on sortOrder:rid,rpid

 

Home Page